SCHEMBL14367156

SCHEMBL14367156

C[C@@H](CCCCNC(=O)[C@H](CCCCNC(=O)CCCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)NCCCCCC(N)=O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1)C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 8/20 0.55
GRPR P30550 3/20 0.43
FOLH1 Q04609 6/20 0.42
CCKAR P32238 2/20 0.37
CCKBR P32239 2/20 0.37
ALB P02768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14367158 0.97 GLP1R (0.52) GLP1RGRPRFOLH1CCKARCCKBR
SCHEMBL12743484 0.97 GLP1R (0.53) GLP1RGRPRFOLH1ALB
SCHEMBL14422366 0.96 GLP1R (0.52) GLP1RGRPRFOLH1CCKARCCKBR
SCHEMBL12743509 0.94 GLP1R (0.51) GLP1RGRPRFOLH1ALB
SCHEMBL14422367 0.91 GLP1R (0.48) GLP1RGRPRFOLH1CCKARCCKBR
SCHEMBL13475019 0.89 GLP1R (0.53) GLP1RGRPRFOLH1CCKARCCKBR
SCHEMBL8122830 0.89 GLP1R (0.53) GLP1RGRPRFOLH1CCKARCCKBR
SCHEMBL8121657 0.87 GLP1R (0.51) GLP1RGRPRFOLH1CCKARCCKBR
SCHEMBL8116094 0.86 GLP1R (0.51) GLP1RGRPRFOLH1CCKARCCKBR
SCHEMBL12972440 0.86 GLP1R (0.51) GLP1RGRPRFOLH1CCKARCCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8663603-B2 Multivalent constructs for therapeutic and diagnostic applications BRACCO SUISSE SA (CH) 2014-03-04 US disclosed
US-20110070165-A1 MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO SUISSE SA (CH) 2011-03-24 US disclosed
US-7910088-B2 Multivalent constructs for therapeutic and diagnostic applications BRACCO SUISSE SA (CH) 2011-03-22 US disclosed
US-7854919-B2 Multivalent constructs for therapeutic and diagnostic applications Bracco, Suisse SA (CH) 2010-12-21 US disclosed
US-20070243139-A1 MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO INTERNATIONAL B.V. (NL) 2007-10-18 US disclosed
US-20070172428-A1 MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO INTERNATIONAL B.V. (NL) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070165-A1 MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS CD47, BCR, CD44 GLP1R 2595/4885GRPR 2491/4885FOLH1 84/4885
US-20070243139-A1 MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS CD47, BCR, CD44 GLP1R 2595/4885GRPR 2491/4885FOLH1 84/4885
US-20070172428-A1 MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS CD47, BCR, CD44 GLP1R 2595/4885GRPR 2491/4885FOLH1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.